TAVR for Native AR — 2026
TAVR for Native AR — 2026
Source: ACC/SCAI/STS Joint Statement
• ACC/SCAI/STS support Medicare coverage for appropriately selected patients.
• AVR: Class I for symptomatic severe AR; also if asymptomatic with LVEF ≤55%.
• SAVR remains standard in operable patients.
• JenaValve Trilogy: first FDA-approved TAVR device for symptomatic severe native AR.
• Require Heart Team + multimodality imaging + FDA-approved device + registry follow-up.
• Evidence remains limited: ~1,500 native-AR TAVR patients vs ~1 million TAVR for AS.
Bottom line: TAVR is now an emerging option for selected symptomatic severe native AR; SAVR remains the established standard.
• Evidence still limited: ~1,500 native-AR TAVR patients vs ~1 million TAVR for AS.
Bottom line: TAVR is emerging as a dedicated option for selected severe symptomatic native AR patients; SAVR remains the established standard.